20:13 , Dec 14, 2018 |  BC Week In Review  |  Financial News

Moderna raises $604M in record IPO, loses $1.4B in trading debut

Moderna Inc. (NASDAQ:MRNA) tumbled out of the gate on Dec. 7, losing $4.40 (19%) to $18.60 in its trading debut for a loss of $1.4 billion in market cap as U.S. stocks across the board...
02:09 , Dec 7, 2018 |  BC Extra  |  Financial News

Moderna sets IPO record with upsized $604M offering

Brushing aside market volatility that has led several biotechs to miss their desired valuations in recent weeks, Moderna Inc. (NASDAQ:MRNA) raised $604.3 million in an upsized IPO late Thursday through the sale of 26.3 million...
18:28 , Nov 30, 2018 |  BC Week In Review  |  Financial News

Moderna proposes terms for record IPO

Moderna Inc. (Cambridge, Mass.) proposed terms for an IPO in which it would raise about $500 million. If the mRNA company succeeds, the deal would be the largest ever on NASDAQ for a precommercial biotech....
20:03 , Nov 28, 2018 |  BC Extra  |  Financial News

Moderna proposes terms for record IPO

Moderna Inc. (Cambridge, Mass.) proposed terms for an IPO in which it would raise about $500 million. If the mRNA company succeeds, the deal would be the largest ever on NASDAQ for a precommercial biotech....
15:59 , Nov 16, 2018 |  BC Week In Review  |  Financial News

At $500M, Moderna files to raise record IPO

mRNA company Moderna Therapeutics Inc. (Cambridge, Mass.) filed on Nov. 9 to raise $500 million in an IPO on NASDAQ, which would mark the largest IPO on the exchange for a development stage biotech. Flagship...
01:39 , Nov 10, 2018 |  BC Extra  |  Financial News

At $500M, Moderna files to raise record IPO

mRNA company Moderna Therapeutics Inc. (Cambridge, Mass.) filed to raise $500 million in an IPO on NASDAQ, which would mark the largest IPO on the exchange for a development stage biotech. Flagship Pioneering launched Moderna...
08:00 , Mar 4, 2013 |  BioCentury  |  Finance

Analyst tracks

Analyst tracks Michael Heider joined Bank am Bellevue as head of research. Heider was co-head of equity research and a member of the executive committee at Helvea S.A. Banker tracks Hunt Henrie joined MedPanel LLC...
07:00 , Jun 25, 2012 |  BC Week In Review  |  Clinical News

Plasmin: Phase I data

Data from 78 evaluable patients in an open-label, dose-escalation, U.S. Phase I trial showed that single doses of 25-175 mg catheter-delivered plasmin into the thrombus led to >=1 serious adverse event in 19 (23%) patients,...
08:00 , Dec 19, 2011 |  BC Week In Review  |  Company News

Zyngenia management update

Zyngenia Inc. , Gaithersburg, Md.   Business: Cancer, Autoimmune, Inflammation   Hired: Daniel Menichella as CBO, formerly SVP of corporate development and strategy at Talecris Biotherapeutics Inc.   Promoted: David Hilbert to chief scientific officer...
07:00 , Jun 13, 2011 |  BC Week In Review  |  Company News

Grifols, Talecris deal

Grifols completed its previously announced acquisition of fellow plasma protein company Talecris in a cash and stock deal that the companies said values Talecris at $26.16 per share, or about $3.4 billion. The price is...